Current State of Translational Medicine

• 17 year innovation adoption curve from discovery into accepted standards of practice

• Lack of innovation adoption planning in the discovery process

• Even if an innovation is accepted as a standard of practice, patients have a 50:50 chance of receiving appropriate care, a 5-10% probability of incurring a preventable, anticipatable adverse event

• Adverse effect anticipation in discovery and surveillance in the trial/post-market process is inadequate

• The market is balking at healthcare inflation, new diagnostics and therapeutics will find increasing resistance for reimbursement